COMMUNIQUÉS West-GlobeNewswire

SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List
13/12/2024
CLEVELAND, Dec. 13, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics has been named to the Crain’s Cleveland Business Fast 50, placing first on the list of rapidly growing, privately held companies ranked by revenue growth [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card
13/12/2024
Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change Incumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has [...]
PharmAla Announces Private Placement
13/12/2024
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Amarin Appoints Peter Fishman Chief Financial Officer
13/12/2024
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today [...]
QHSLab (OTCQB:USAQ) and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology
13/12/2024
NSF Recognition: A Testament to Innovation Driving Strategic Growth and Shareholder Value WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ) , a leading provider of digital [...]
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13/12/2024
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple [...]
Sienna Announces December Dividend
13/12/2024
MARKHAM, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
13/12/2024
Same-day dosing results comparable to next day dosing schedules LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with [...]
iTeos Therapeutics présente les données intermédiaires de l’essai clinique A2A-005, ainsi que les données translationnelles et précliniques relatives à l’inupadénant lors du congrès d’immuno-oncologie de l’ESMO
13/12/2024
- L’essai de phase 2 A2A-005 portant sur l’inupadénant + carboplatine/pémétrexed a démontré un taux de réponse globale (TRG) de 63,9 % et une SSP médiane de 7,7 mois pour tous les patients évaluables sur l’ensemble des [...]
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
13/12/2024
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria [...]
Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
13/12/2024
INX-315 was safe and well tolerated in monotherapy dose escalation INX-315 monotherapy demonstrated antitumor activity in heavily pretreated patients with ER+/HER2- breast cancer and CCNE1-amplified ovarian cancer [...]
Dentsply Sirona Declares Quarterly Cash Dividend
13/12/2024
CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of [...]
At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy
13/12/2024
With its adoption of “zero-footprint” technology, ZEfiRO guarantees clinician and operators immediacy and usability in reading images wherever they are, with a positive impact on the management of diagnosis and [...]
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
13/12/2024
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent [...]
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13/12/2024
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/12/2024
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13/12/2024
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the [...]
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
13/12/2024
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]

Pages